Global Urothelial Carcinoma Treatment Market

Global Urothelial Carcinoma Treatment Market size was estimated at USD 2.9 billion in 2021, and it is expected to reach USD 4.73 Billion in 2028 with a CAGR of 18.6% during the forecast period 2022-2028. The growing majority of cancer all over the globe, rising government initiatives for cancer treatment, and the rise in cancer research are expected to drive the cancer treatment market over the predicted years. The emergence of treatment-resistant clones is a crucial impediment to healing patients with urothelial carcinoma. Urothelial carcinoma imposes the stage for developing resistance. Urothelial carcinoma is distinguished by extensive mutational heterogeneity, noticeable in patients with early-stage disease. Chemotherapy and immunotherapy act as selective pressures shaping the evolution of urothelial carcinoma throughout the disease.

What is the Urothelial Carcinoma Treatment Market?

Urothelial carcinoma is a malignant neoplasm shown from transitional epithelium, appearing mostly in the urinary bladder, renal pelvis or ureters; continually papillary. These carcinomas are categorized according to the degree of anaplasia. Urothelial cell carcinoma is a type of cancer that usually happens in the urinary system: urinary bladder, kidney and accessory organs. It is the most typical bladder, ureter, urethra, and urachus cancer. Urothelial cell carcinoma is also known as transitional cell carcinoma. Bladder transitional cell carcinoma is the most familiar tumor of the whole urinary system, and Transitional cell carcinoma is the most common direct neoplasm of the urinary bladder.

Growth Drivers

Increase in the number of private Treatment Centers

The number of private treatment centers is increasing across the globe as there is a rising demand for diagnostic imaging techniques and a growing responsibility on public hospitals due to the limited number of imaging modalities at their disposal. In January 2021, FUJIFILM Corporation spread NURA, a medical screening center concentrating on cancer screening in Bangalore, India. FUJIFILM DKH LLP (FUJIFILM DKH) and Dr. Kutty’s Healthcare work at this medical screening center. FUJIFILM DKH LLP is a collaborative venture of FUJIFILM and Dr. Kutty’s Healthcare (DKH), which runs hospitals and screening centers in India and the Middle East.

Opportunities

Increase in the Cancer Patients

Urothelial cancer is the 9th most typical malignancy globally, with nearly 2.4 million patients and 420,000 recently analyzed cases yearly. Around 59% of bladder cancer cases occur in developed regions like the USA and Europe. Also, novel drugs developed by pharmaceutical companies are expected to anticipate opportunities for substantial growth of the urothelial cancer treatment market globally.

Requests for cancer screening

Governments in progressive countries and prior care doctors suggest cancer screening tests for patients to detect cancer early and bring down the mortality rate. The U.S. Preventive Services Task Force suggests screening for cancer starting at 50 years of age to 75 years of age in the U.S. as a means of preventing disease incidence and providing early-stage treatment. Canada has also executed biennial colorectal cancer screening guidelines for individuals aged 50 to 74 years.

Restraints

Growing adoption of remodeled diagnostic imaging systems

Multiple hospitals in developing countries cannot invest in diagnostic imaging equipment due to higher costs, poor repayment rates, and budgetary constraints. However, hospitals that cannot invest in new imaging techniques choose to opt for refurbished ones due to the high need for diagnostic imaging techniques in these countries. Refurbished systems are priced lower than new techniques and are approximately 40% to 60% of the original price of the equipment.

Pre-Covid-19 impact on Global Urothelial Carcinoma Treatment Market

Before the covid-19 outbreak, the treatment of Urothelial carcinoma affects surgery, chemotherapy and radiotherapy. The difficulties in diagnosing Urothelial carcinoma include Urine tests, Ureterostomy, Intravenous pyelogram (IVP), retrograde pyelography, C.T. scan, MRI scan and Chest X-ray. At the same time, the treatment with surgery contains open surgery, laparoscopic surgery and percutaneous endoscopic surgery. Chemotherapy treatment usually concerns the treatment with a combination of drugs. The combinations contain gemcitabine and cisplatin, gemcitabine and carboplatin, methotrexate, vinblastine, doxorubicin and cisplatin. Radiotherapy is not continually utilized for transitional cell carcinoma of the kidney or ureter. The patient may include radiotherapy to the area of the ureter or kidney if patients are not fit sufficiently to maintain an operation or cancer has extended into the surrounding tissue.

Covid-19 impact on Global Urothelial Carcinoma Treatment Market

During the covid-19 outbreak, the WHO officially declared the outbreak of COVID-19 a pandemic, a mixture of preferred pharmaceutical and biopharmaceutical companies and small startups had stepped forward to create treatments and vaccines that target the infection induced by the novel coronavirus. The COVID-19 outbreak has seriously affected the availability of hospital resources worldwide. It has been primarily operated by dramatically declining inpatient and outpatient services for other conditions and enforcing infection defense and control efforts. The number of urothelial cancer screening and diagnostic procedures decreased precipitously, with governments worldwide being impacted by the pandemic.

Post Covid-19 impact on Global Urothelial Carcinoma Treatment Market

After the covid-19 outbreak, a new treatment for progressive urothelial cancer was sufficient with modest side effects in an international, multi-center phase 2 clinical trial led by Weill Cornell Medicine and New York-Presbyterian investigators. The trial population had advanced despite treatment with platinum-based chemotherapy and immune-boosting “checkpoint inhibitors, and the general had a median of 3 previous sequences of therapy. Sustained decreases observed treatment with S.G. in tumor size for 31 patients (27 percent), including complete tumor disappearance in six patients. The most common unbearable outcomes were very low white blood cell count in 34 percent (with fever in 10 percent) and extreme diarrhea in 9 percent, driven by dose adjustment and adequate supportive care. “The bottom line is that S.G. means another opportunity for patients with this antagonistic type and stage of cancer—and it’s even nice that it has a distinct target and mechanism of action reached to other drugs for this indication.

By Type Segmental Analysis

Based on Type segmental analysis, the market is segmented into Non-Invasive Urothelial Carcinoma treatment and Invasive carcinoma treatment. Non-invasive urothelial neoplasms describe the prevalence of bladder malignancies at initial diagnosis. Non-invasive urothelial neoplasms were submitted into the World Health Organization classification scheme of urinary system tumors in 1973 and were then maintained and updated in the WHO 2004 and 2016 classification system.

By Treatment segmental Analysis

The market is segmented into Immunotherapy, Radiotherapy, and Chemotherapy based on treatment segmental analysis. Unlike chemotherapy, which works instantly on cancerous tumors, immunotherapy treats patients by working on their immune systems. Immunotherapy can promote the immune reaction in the body and teach the immune system to identify and destroy cancer cells. That is why immunotherapy has the largest share in the global urothelial carcinoma market.

By End-User segmental Analysis

Based on End-User segmental analysis, the market is segmented into Hospital Pharmacies and Retail Pharmacy. The hospital’s pharmacy segment is estimated for the largest share of the urothelial carcinoma treatment market. The increasing number of patients seeing hospitals, the increasing number of in-house treatment procedures conducted in hospitals, and increasing awareness concerning early diagnosis are the primary driving element for this market.

By Regional segmental Analysis

The market is segmented into North America, Europe, Asia-Pacific, South America, and The Middle East & Africa based on regional segment analysis. North America is likely to dominate the urothelial carcinoma treatment market due to the increasing prevalence of bladder cancer investment in research and development of new bladder cancer treatment. According to the North America cancer society report, about 79030 cases of bladder cancer were reported in 2017 in the U.S. Europe is the second-largest market for urothelial carcinoma treatment, observed by Asia-Pacific. Due to increasing attention concerning the early diagnosis of bladder cancer and developed healthcare infrastructure with an increasing majority of urothelial cancer. Asia-Pacific delivers the fastest growth in the market due to the low cost of R&D. India and China is predicted to be the fastest-growing market for bladder cancer treatment.

Competitors Analysis

The companies include GlaxoSmithKline plc, Genentech, Inc., Novartis AG, Dendreon, Merck KGaA, Eisai Co., Sanofi S.A., Bristol-Myers Squibb and other prominent players in the global urothelial carcinoma treatment market. Key Stakeholders

• Market research and consulting firms
• Urothelial Carcinoma treatment Associates
• Local Governments
• Regulatory bodies
• Urothelial Carcinoma Treatment Market
• Suppliers
• Service Providers

Recent Developments

• In January 2019, GlaxoSmithKline PLC obtained TESARO Inc., an oncology-based biopharmaceutical organization, encouraging the development of GSK’s pipeline and business knowledge in oncology.
• In January 2020, Merck and Co. Inc. received ArQule Inc., a biopharmaceutical organization is concentrating on kinase inhibitor revelation and advancement for the therapy of patients with cancer.

Scope of the Report

Report Attribute	Details
Market Size Value in 2021	USD 2.9 Billion
The revenue forecast in 2028	USD 4.73 Billion
Growth Rate	CAGR of 18.6 % from 2022 to 2028.
Historical data	2017 – 2020
Forecast period	2022 – 2028
Region covered	North America, Europe, Asia-Pacific, South America, and Middle East & Africa
Key companies Profiled	The Companies include GlaxoSmithKline plc, Genentech, Inc., Novartis AG, Dendreon, Merck KGaA, Eisai Co., Sanofi S.A. and Bristol-Myers Squibb are the key players.

Market Modelling

By Type

• Non-Invasive Urothelial Carcinoma Treatment
• Invasive Urothelial Carcinoma Treatment

By Treatment

• Immunotherapy
• Radiotherapy
• Chemotherapy

By End-User

• Hospital Pharmacy
• Retail Pharmacy
• Others

By Region

• North America
• Europe
• Asia-Pacific
• South America
• The Middle East & Africa

Influenza Diagnostics Market

Global Instrument Infection Control Market

Fats and Oils Market

Astaxanthin Market

Global VoIP Phone Market

Lithium Ion Battery Market Report

Global and Europe Electric Bicycle Market Report

India Automotive Sensors Market Report

Zeolite Market